Health is a major issue for many people, and the maintainance of good health has always been an aspiration of medicine and science. Many pioneering discoveries in recent years made it possible to think about completely new therapeutic approaches. Thus, the search for new drugs and therapies has become a key task of life science and pharmaceutical research.

Electrogenic membrane proteins such as ion channels, transporters and ion pumps are of major importance to the human organism with respect to signal transduction and metabolism. They therefore belong to the most promising targets for future pharmacological developments.

IonGate Biosciences GmbH operates in the field of preclinical pharmaceutical drug research, specialising in these membrane proteins. Apart from in-house technology development, IonGate offers its services in a range of areas such as safety pharmacology, target characterisation, screening by means of electrophysiological methods as well as assay development.

People

Thiemo Gropp (Managing Director)

Wolfgang Lerch (Managing Director)

Bela Kelety (Director of Research and Development)

Stefan Schork (Director of Sales)

View more details about the people at IonGate Biosciences

News

Life sciences briefing: Wednesday, Jan. 16, 2008

January 16, 2008 7:09 pm

TODAY’S HEADLINES: Drug-screening tool maker IonGate Bio raises €4.6M (release) Protein-drug maker Molecular Partners gets $5M up front in Centocor… Continue reading ⟩